Navigation Links
Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
Date:12/18/2007

discovery of a new biomarker for brain cancers by collaborators at NIH, the Company is developing new drugs for the treatment of glioblastoma multiforme (GMB), the most common and most aggressive type of primary brain cancer in adults and, to a much lesser extent, in children.

About Westpark Capital, Inc.

WestPark is a leading full-service investment bank dedicated to providing innovative, professional financial services to emerging growth companies headquartered in Los Angeles, California. WestPark provides a wide range of services for both private and public companies, as well as to individuals and institutional investors worldwide. WestPark is a leading financial advisor for emerging growth companies. WestPark offers its clients a comprehensive range of services including WRASPs, initial public offerings, reverse mergers, follow-on offerings and private placements, and financial advisory services.

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," "anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove
'/>"/>

SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
2. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 KaloBios Pharmaceuticals, Inc. (Nasdaq: ... of the KB001-A development program, including an update on ... KB001-A Collaboration Update KaloBios announced that ... regain all rights to KaloBios, KB001-A program. Under this ... 2010 has been terminated. Under that collaboration agreement, Sanofi ...
(Date:7/28/2014)... July 28, 2014  Serco Inc., a provider ... Company has been awarded a re-compete contract to ... and its Deployable Medical Systems.  Serco will provide ... to provide world-class healthcare to meet warfighter and ... the globe. The five year contract has a ...
(Date:7/28/2014)... Colo. , July 28, 2014  Array ... financial results for the fourth quarter and ... a conference call to discuss those results ... Chief Executive Officer and Michael Carruthers ... call.Conference Call InformationDate:Tuesday, August 12, 2014Time:9:00 a.m. ...
Breaking Medicine Technology:KaloBios Provides Update on KB001-A Partnership and Clinical Status 2KaloBios Provides Update on KB001-A Partnership and Clinical Status 3KaloBios Provides Update on KB001-A Partnership and Clinical Status 4KaloBios Provides Update on KB001-A Partnership and Clinical Status 5KaloBios Provides Update on KB001-A Partnership and Clinical Status 6Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2
... -First Combination Study of a MET and EGFR Inhibitor-, ... (Nasdaq: EXEL ) today announced that it has ... non-small cell lung cancer (NSCLC) who have had,progressive disease ... a small molecule that simultaneously inhibits the MET, RET ...
... ASHBURN, Va., Jan. 4 Innocoll, Inc., ... first of a series of,planned phase 2 ... subsidiary,Innocoll Technologies Ltd, to investigate CollaRx(R) BUPIVACAINE ... has commenced dosing., Innocoll,s BUPIVACAINE SURGICAL ...
Cached Medicine Technology:Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 2Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 3Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 4Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 2Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 4
(Date:7/28/2014)... Camp Soaring Eagle today announced it ... Cornville, AZ. The nonprofit organization, founded in July ... to attend medically supervised camps at no cost ... a variety of programs to Arizona families and ... illnesses including: Illness Specific Camping Weekends, Illness Specific ...
(Date:7/28/2014)... WI (PRWEB) July 28, 2014 Quincy ... Prevagen® , is pleased to announce the release of ... by company president and co-founder Mark Underwood. , The ... health information, offering useful techniques for readers to improve ... as an unavoidable conclusion, The Brain Health Guide provides ...
(Date:7/28/2014)... Randy Dotinga HealthDay Reporter ... know it takes humans just milliseconds to look at someone,s ... a new study finds that certain facial features seem to ... The shape and size of the mouth, for example, appear ... are keys to attractiveness. The study findings suggest ...
(Date:7/28/2014)... Ticket Down is reliable source for ... TX at the Cotton Bowl. The 2014 Guinness International ... it is an eight team tourney. The tournament participants ... from La Liga, Serie A, English Premier League, and Superleague ... on the pitch include: Manchester United, Manchester City, Olympiacos, ...
(Date:7/28/2014)... Glutamine is the most abundant single ... be conditionally essential during times when the body undergoes ... & Immune System Support. , Having a heavy work ... supplementing with additional glutamine may be advantageous. Glutamine supplementation ... body, digestion and immune system function. Stress on the ...
Breaking Medicine News(10 mins):Health News:Camp Soaring Eagle Announces New Camp Site 2Health News:Camp Soaring Eagle Announces New Camp Site 3Health News:Quincy Bioscience Launches the Fourth Edition of The Brain Health Guide 2Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3
... ADHD who carry a specific type of dopamine ... (MPH) than those without the genotype, according to ... The findings come from the first-ever placebo-controlled ... school age children to evaluate variants of the ...
... took the banned substance were leaner and ran faster, ... hormone, a substance frequently implicated in sports doping scandals, ... shows. , Australian researchers gave 96 non-professional athletes aged ... saline placebo. Participants included 63 men and 33 women. ...
... NEW ORLEANS, LA (May 3, 2010) Researchers have ... bowel disease, while other science shows that intra-abdominal fat ... patients, and new technology shows promising results for improvements ... the studies being presented at Digestive Disease Week (DDW) ...
... 2010) The results of new research results published ... the American College of Surgeons show that a ... hospital surgical ward. Postoperative pneumonia is a ... most common infectious complication after urinary tract and wound ...
... and without symptoms, screening mammography may be inappropriate, researchers say ... under the age of 40 result in many return visits ... a new study finds. , Almost 30 percent of ... getting mammograms, although they,re not generally recommended until age 40. ...
... later outcomes, studies show , MONDAY, May 3 (HealthDay ... critical prenatal, maternal and environmental factors can be in shaping ... things, the studies found that kids who stayed glued to ... who smoked or took antidepressants during pregnancy had raised risks ...
Cached Medicine News:Health News:Research helps end guesswork in prescribing ADHD drug 2Health News:Human Growth Hormone Does Boost Athletic Performance 2Health News:Human Growth Hormone Does Boost Athletic Performance 3Health News:Pancreatic cancer: Minimally invasive treatments and possible links to GI diseases 2Health News:Pancreatic cancer: Minimally invasive treatments and possible links to GI diseases 3Health News:Pancreatic cancer: Minimally invasive treatments and possible links to GI diseases 4Health News:Pancreatic cancer: Minimally invasive treatments and possible links to GI diseases 5Health News:Pancreatic cancer: Minimally invasive treatments and possible links to GI diseases 6Health News:Surgeons' pilot prevention program reduces incidence of postoperative pneumonia 2Health News:Effects of TV, Drug Exposures in Early Life May Be Long-Lasting 2Health News:Effects of TV, Drug Exposures in Early Life May Be Long-Lasting 3
... ORTHOSTAR table is the most ... It was designed for both ... traction with an integrated shoulder ... special purpose operating table for ...
... theatre is ready for all current and future ... design allows a quick, problem-free conversion to meet ... connected securely and sturdily to MARS through a ... should ever be a problem in spite of ...
... Exclusive, 210° Top Rotation provides ... purpose surgery. The Hercules 6700B eliminates ... during head-end procedures, while providing ample ... to sit during procedures. Removable back ...
... schaereraxis 200/300 product range includes ... been designed for the varied ... in the surgical practice, in ... A favorable price-performance ratio takes ...
Medicine Products: